Clinical Trials · NCT04140409

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

TerminatedPhase 4Octreotide (Prohibited)
Phase
Phase 4
Recruitment status
Terminated
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Enrollment
10
Start date
Feb 2016
Locations
See registry
Primary endpoint
Treatment succes vs treatment failure
View Octreotide compound reference